Recent clinical advances using amyloid beta (A?) monoclonal antibodies that interact with both soluble Abeta oligomers and insoluble fibrillar A?, have demonstrated a reduction in A? burden correlating with a slowing of cognitive decline in early Alzheimer’s patients and have renewed confidence in the A? approach. Cognition Therapeutics has a first candidate in the clinic and has back-up candidates moving through its late preclinical pipeline.
By leveraging the expertise of its scientists at characterizing oligomeric proteins and their unique screening know-how in this area, Cognition Therapeutics has also initiated a discovery program for drug candidates to treat Parkinson’s dementia.